Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
Aram F. Hezel(University of Rochester Medical Center), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Hui Zheng(Harvard University), Diana Harris(Bristol Royal Hospital for Children), Alok A. Khorana(Cleveland Clinic), Susan Sheehan(Jackson Laboratory), Thomas A. Abrams(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), A. John Iafrate(Massachusetts General Hospital), Lipika Goyal(Stanford Medicine), Marcus Smith Noel(University of Rochester), Janet E. Murphy(Harvard University), Gregory C. Connolly(University of Rochester), David P. Ryan(East Carolina University), Andrea Baran(Hospital of the University of Pennsylvania), Kimmie Ng(Dana-Farber Cancer Institute), Megan M. Herr(Roswell Park Comprehensive Cancer Center), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Ollivier Hyrien(Fred Hutch Cancer Center), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Eileen Regan(Dana-Farber Cancer Institute), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Jill N. Allen(Harvard University), Jason E. Faris(Royal Marsden NHS Foundation Trust)
Cited by 58
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k